April 2, 2025 8:24am

Ahead of the implementation of a raft of Trump’s “reciprocal tariffs” that will “start with all countries”

So, what and which shackles am I “personally” being releases from …volatility, our national dignity and fear from “others” pricing

Pre-Open Indications: 6 Positive and 2 Negative Indications

 

Breaking: Private companies added 155,000 jobs in March, more than expected, ADP says. Companies added 155,000 jobs in March, a sharp increase from the upwardly revised 84,000 in February and better than the Dow Jones forecast for 120,000, according to ADP. On the wage side, earnings rose by 4.6% year over year for those staying in their positions and 6.5% for job changers. The gap between the two matched a series low.

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief …

I am NOT often wrong and always consider doubt of some market and sector share pricing movements

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Tuesday’s night’s … RegMed Investors (RMi) Closing Bell:  bumpy session … https://www.regmedinvestors.com/articles/13862

RegMed Investors (RMi) Research Note:Harvard Apparatus GT (OTCQB: HRGN), formerly Biostage (OTCQB: BSTG); The chokehold got tighter cutting-off any capacity to lift multiple going concern at-risk marker … https://www.regmedinvestors.com/articles/13812

 

Wednesday; the pre-open Dow futures are DOWN -0,63% or (-203 points), the S&P futures DOWN -0.85% or (-47 points) and the Nasdaq futures are DOWN -1.03% or (-202 points)

  • Stock futures are flip-flopping on Wednesday.4/2
  • European markets were lower bracing for a raft of fresh trade tariffs due,
  • Asia-Pacific markets were mixed Wednesday.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Tuesday: The Dow closed DOWN -11.80 points or -0.03%, the S&P closed UP +21.22 points or +0.38% while the Nasdaq closed UP +150.60 points or +0.87%

Economic Data Docket: ADP employment report for March

  • Economists are expecting that private companies added 120,000 jobs last month, up from the 77,000 jobs added in February.

 

Q2- April – 1 negative close

  • Q1/25 – March, 10 positive and 11 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Positive Indications:

  • Alnylam Pharmaceuticals (ALNY) closed down -$14.26 after Monday’s +$1.46) and Friday’s -$2.56 with a positive +1.43 or +0.56%
  • CRISPR Therapeutics (CRSP) closed down -$0.89 after Monday’s -$2.92 and Friday’s -$1.05 with a positive +$0.34 or +1.03%
  • Ionis Pharmaceuticals (IONS) closed down -$2.91 after Monday’s -$1.09 with a positive +$0.39 or +1.43%
  • Moderna (MRNA) closed down -$1.19 after Monday’s -$2.88 after Friday’s -$1.00 with a positive +$0.08 or +0.29%
  • Mesoblast (MESO) closed down -$0.58 with a positive +$0.49 or +4.12%
  • Ultragenyx Pharmaceuticals (RARE) closed down -$2.37 after Monday’s -$1.54 Friday’s -$1.07 with a positive +$0.30 or +0.89% aftermarket

Negative Indications:

  • bluebird bio (BLUE) closed up +$0.37 after Monday’s +$0.87 with a negative -$0.10 or -1.90%
  • Lenz Therapeutics (LENZ) closed up +$0.30 with a negative -$0.95 or -3.65%

 

The BOTTOM LINE:  Head down, ears covered, eyes on a swivel 

Think about it; one of the biggest problems with the cell and gene therapy sector’s share pricing is …  99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital.

  • However, “our” universe’s share pricing is still “dangling” beneath upcoming Q4/2024 earnings releases with no umbrella although some sector companies released pre-lim unaudited snapshots of Q4 and FY2024 at JP Morgan Healthcare Conference!

I think speculative behavior in this current market has ascended to a level beyond common sense

  • Merger and acquisition (M&A) activity; sector companies will seek opportunities to sell to better financed companies that can "deal with these additional costs associated of R&D and escalating SG&A.”

NOT much has changed, as I have written, “uncle algo and his trading dwarfs” determine the heights or lows of share pricing”

  • Prepare for more market volatility related to inflation oriented econs …

What could 2025 have in store for the capital access space as Partners are the gift of life!

  • "You'll see a number of cell and gene therapy comandantes drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in the market… capital expansion is second.

I seem to be asking a question followed by a question …

  • Do we need to brace ourself for more economics and their down trending affect?
  • Is this market STILL “bubblicious” my concerns are macroeconomic and valuation

 Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.